A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
Published on 24 Nov 2020
Share
Publication

Materiality of Superbugs

Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimicrobial resistance (AMR). If left unchecked, AMR is set to substantially undermine the global economy’s financial recovery and future outlook. Here, Mara Lilley and Sana Johnson run through the main risks and opportunities presented by superbugs for pharma companies and resources available for navigating through them.

Explore further

News

Work starts on metrics for the 2020 AMR Benchmark

The Access to Medicine Foundation has started the methodology review for the next Antimicrobial Resistance Benchmark. The Foundation is consulting a wide range of experts and stakeholders to explore how to refine its analysis of pharmaceutical company responses to antimicrobial resistance.
Publication

2020 Antimicrobial Resistance Benchmark

The 2020 Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics.
Best Practice

Case 3: Broad generic antimicrobial portfolio, Cipla

Generic medicine manufacturer Cipla stands out for its stewardship practices. It manufactures a wide range of antibiotics, such as the low-cost azithromycin and amoxicillin, which are both widely used for a variety of infections.

Get in touch

Back to top |